BACKGROUND: African Americans are more likely to be diagnosed with metastatic
colorectal cancer than whites and have shorter survival once they are diagnosed. In this …

Background The objective of this study was to evaluate the association between self‐
identified race and overall survival (OS), progression‐free survival (PFS), and response to …

Importance Randomized clinical trials have defined the survival benefit provided by the
addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer …

Purpose Previous studies documented significant increase in overall survival for metastatic
colorectal cancer (CRC) since the late 1990s coinciding with the introduction and …

Background Black patients with metastatic colorectal cancer have inferior survival compared
to white patients. The purpose of this study was to examine disparity in specialist …

Abstract Background In United States Hispanics have disparities in the presentation and
outcome of colorectal cancer (CRC) largely attributed to their late presentation and lower …

Background Randomized clinical trials have defined the survival advantage with the
addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer …

Purpose Recently, multiple clinical trials have demonstrated improved outcomes in patients
with metastatic colorectal cancer. This study investigated if the improved survival is race …

Background Black patients and underinsured patients with colorectal cancer (CRC) present
with more advanced disease and experience worse outcomes. The study aim was to …

Background As of 2006, bevacizumab was available for the treatment of metastatic
colorectal cancer (mCRC) in British Columbia (BC). This study compares survival between …